Feed / VERA

Vera Therapeutics, Inc.

VERA

Healthcare · 32.28 +3.4% today

Participation confirmed · construction unavailableMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Vera Therapeutics, Inc.'s move is being confirmed by its market group.

No new filing conclusion is available. 10 of 16 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.

Company+3.4% todayVolume comparison unavailable
Market group10 of 16 activeClinical Biopharmaceuticals · inactive
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind VERA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AZNAstraZeneca PLCcompetitorMay 7, 2026

Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be approved products: the reformulated steroid (TARPEYO ® ) from Asahi Kasei Corp., the anti-APRIL monoclonal antibody (VOYXACT ® ) from Otsuka Pharmaceutic…

BIIBBiogen Inc.competitorMay 7, 2026

Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be approved products: the reformulated steroid (TARPEYO ® ) from Asahi Kasei Corp., the anti-APRIL monoclonal antibody (VOYXACT ® ) from Otsuka Pharmaceutic…

Depended on by

CLYMClimb Bio, Inc.competitorMay 7, 2026

The competitive landscape for CLYM116 includes, but is not limited to, companies developing biologics targeting APRIL or BAFF/APRIL for IgAN, such as Otsuka Pharmaceutical Co., Ltd, which has an approved treatment for IgAN, VOYXACT (sibeprenlimab), Novartis A…

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

VERA is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.